Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis - The
Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer - European Journal of Cancer
Final analysis of progression-free survival in the PALOMA-3 study... | Download Scientific Diagram
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - Annals of Oncology
Real-world effectiveness of palbociclib plus fulvestrant in advanced breast cancer: Results from a population-based cohort study - ScienceDirect
Patient Case Lessons: Endocrine Management of Advanced Breast Cancer - Clinical Breast Cancer
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Open—Cancer Horizons pro and con discussion - ESMO Open
Ribociclib Improves Survival in Advanced Breast Cancer - National Cancer Institute
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - Annals of Oncology
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial - The Lancet Oncology
Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice | Breast Cancer Research | Full Text
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients - ESMO Open
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18) | SpringerLink
ASCO 2021: Addition of Palbociclib to Fulvestrant Attains Overall Survival Benefit in Advanced Breast Cancer With Update of PALOMA-3 | PracticeUpdate
Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial | Nature Medicine
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | Semantic Scholar
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer | NEJM
Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2–advanced breast cancer: GEICAM/2014–12 (FLIPPER) - European Journal of Cancer
Kaplan-Meier curves of progression-free survival among patients in... | Download Scientific Diagram
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | NEJM
Palbociclib Demonstrates Prolonged OS/PFS When Initiated in Metastatic Breast Cancer
IBRANCE® (palbociclib) + fulvestrant|Non-prespecified Analyses|Safety Info
